Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer
STUDY OBJECTIVE--Comparison of tamoxifen and mastectomy in treatment of breast cancer in elderly patients. DESIGN--Randomised trial of treatment of operable breast cancer by wedge mastectomy or tamoxifen, with median follow up 24 and 25 months respectively (range 1-63). SETTING--University hospital;...
Gespeichert in:
| Veröffentlicht in: | BMJ 1988-08, Vol.297 (6647), p.511-514 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 514 |
|---|---|
| container_issue | 6647 |
| container_start_page | 511 |
| container_title | BMJ |
| container_volume | 297 |
| creator | Robertson, J. F. Todd, J. H. Ellis, I. O. Elston, C. W. Blamey, R. W. |
| description | STUDY OBJECTIVE--Comparison of tamoxifen and mastectomy in treatment of breast cancer in elderly patients. DESIGN--Randomised trial of treatment of operable breast cancer by wedge mastectomy or tamoxifen, with median follow up 24 and 25 months respectively (range 1-63). SETTING--University hospital; most patients from primary catchment area. PATIENTS--135 consecutive patients with breast cancer aged over 70 with operable tumours (less than 5 cm maximum diameter); 68 were allocated to tamoxifen group and 67 to mastectomy group. Histological diagnosis by biopsy. Two incorrect randomisations in each group. Patient characteristics similar in the two groups and all under care of one surgical team. INTERVENTIONS--Mastectomy group received wedge mastectomy plus excision of symptomatic axillary lymph nodes. Tamoxifen group received continuous treatment with tamoxifen 20 mg twice daily. Patients in tamoxifen group received wedge mastectomy if there was sign of local progression. Those in mastectomy group received further excision or radiotherapy for locoregional recurrence and when local treatments had been exhausted or metastatic disease diagnosed they received tamoxifen. END POINT--Treatment efficacy was assessed by local control of disease and by survival. MAIN RESULTS--Mortality from metastatic cancer in tamoxifen group was 7 (10.6%) and in mastectomy group 10 (15.3%) (NS). There was no difference in survival between the two groups. In mastectomy group 70% remained alive and free of local recurrence at 24 months; in tamoxifen group only 47% remained alive and free of local progression. In mastectomy group locoregional recurrence occurred in 16 patients and metastatic disease in 13; in tamoxifen group locoregional progression occurred in 29 patients and metastatic disease in seven. CONCLUSIONS--As a high proportion of patients treated with tamoxifen eventually required surgery treatment of elderly patients with breast cancer should include mastectomy. Optimum treatment may include both mastectomy and tamoxifen. |
| doi_str_mv | 10.1136/bmj.297.6647.511 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1840371</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>29700597</jstor_id><sourcerecordid>29700597</sourcerecordid><originalsourceid>FETCH-LOGICAL-b515t-e8c43e555e4a0b88be0522a46563f0cfcffaf4bcf9df916cbe3befbedb42755a3</originalsourceid><addsrcrecordid>eNqFkU2rEzEUhoMo13K9ezfCgOBGpiaTz9kIUtSq5bpRcReS9OTeqTOTMUn19t-bMqV-bFyF8D7n5RwehB4TvCSEihd22C2bVi6FYHLJCbmHFoQJVXNF6X20wC1va0WoeoiuUtphjBsqVSv4BbqghLZEtgtkVmGYTOxSGKvgq8GkDC6H4VD97PJtlc0Q7joPY-VDrHIEk7vxpoJ-C7E_VFP5wpjTDIcJorE9VLZwKVfOjA7iI_TAmz7B1em9RJ_fvP60Wtebj2_frV5tassJzzUoxyhwzoEZbJWygHnTGCa4oB4777w3nlnn261viXAWqAVvYWtZIzk39BK9nHunvR1g68pe0fR6it1g4kEH0-m_k7G71TfhhyaKYSpJKXh2Kojh-x5S1kOXHPS9GSHsk5aKUSYpL-DTf8Bd2MexHKeJlIIRSklTKDxTLoaUIvjzKgTroz9d_OniTx_96eKvjDz584TzwMnW73yXcojnuHRgzFtZ8nrOu2Lx7pyb-E0LSSXX119W-uv7DaUfrtd6XfjnM3_c5L_b_QI37MB6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776413312</pqid></control><display><type>article</type><title>Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>Alma/SFX Local Collection</source><creator>Robertson, J. F. ; Todd, J. H. ; Ellis, I. O. ; Elston, C. W. ; Blamey, R. W.</creator><creatorcontrib>Robertson, J. F. ; Todd, J. H. ; Ellis, I. O. ; Elston, C. W. ; Blamey, R. W.</creatorcontrib><description>STUDY OBJECTIVE--Comparison of tamoxifen and mastectomy in treatment of breast cancer in elderly patients. DESIGN--Randomised trial of treatment of operable breast cancer by wedge mastectomy or tamoxifen, with median follow up 24 and 25 months respectively (range 1-63). SETTING--University hospital; most patients from primary catchment area. PATIENTS--135 consecutive patients with breast cancer aged over 70 with operable tumours (less than 5 cm maximum diameter); 68 were allocated to tamoxifen group and 67 to mastectomy group. Histological diagnosis by biopsy. Two incorrect randomisations in each group. Patient characteristics similar in the two groups and all under care of one surgical team. INTERVENTIONS--Mastectomy group received wedge mastectomy plus excision of symptomatic axillary lymph nodes. Tamoxifen group received continuous treatment with tamoxifen 20 mg twice daily. Patients in tamoxifen group received wedge mastectomy if there was sign of local progression. Those in mastectomy group received further excision or radiotherapy for locoregional recurrence and when local treatments had been exhausted or metastatic disease diagnosed they received tamoxifen. END POINT--Treatment efficacy was assessed by local control of disease and by survival. MAIN RESULTS--Mortality from metastatic cancer in tamoxifen group was 7 (10.6%) and in mastectomy group 10 (15.3%) (NS). There was no difference in survival between the two groups. In mastectomy group 70% remained alive and free of local recurrence at 24 months; in tamoxifen group only 47% remained alive and free of local progression. In mastectomy group locoregional recurrence occurred in 16 patients and metastatic disease in 13; in tamoxifen group locoregional progression occurred in 29 patients and metastatic disease in seven. CONCLUSIONS--As a high proportion of patients treated with tamoxifen eventually required surgery treatment of elderly patients with breast cancer should include mastectomy. Optimum treatment may include both mastectomy and tamoxifen.</description><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>EISSN: 1756-1833</identifier><identifier>DOI: 10.1136/bmj.297.6647.511</identifier><identifier>PMID: 3139179</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Aged ; Aged, 80 and over ; Breast - pathology ; Breast - surgery ; Breast cancer ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cause of Death ; Combined Modality Therapy ; Disease progression ; Female ; Grade 3 ; Histology ; Humans ; Lymph Node Excision ; Mastectomy ; Neoplasia ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Older adults ; Prospective Studies ; Radiotherapy ; Random Allocation ; Relapse ; Risk Factors ; Simple mastectomy ; Tamoxifen - therapeutic use</subject><ispartof>BMJ, 1988-08, Vol.297 (6647), p.511-514</ispartof><rights>Copyright 1988 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Aug 20, 1988</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b515t-e8c43e555e4a0b88be0522a46563f0cfcffaf4bcf9df916cbe3befbedb42755a3</citedby><cites>FETCH-LOGICAL-b515t-e8c43e555e4a0b88be0522a46563f0cfcffaf4bcf9df916cbe3befbedb42755a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/29700597$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/29700597$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,780,784,803,885,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3139179$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robertson, J. F.</creatorcontrib><creatorcontrib>Todd, J. H.</creatorcontrib><creatorcontrib>Ellis, I. O.</creatorcontrib><creatorcontrib>Elston, C. W.</creatorcontrib><creatorcontrib>Blamey, R. W.</creatorcontrib><title>Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer</title><title>BMJ</title><addtitle>BMJ</addtitle><description>STUDY OBJECTIVE--Comparison of tamoxifen and mastectomy in treatment of breast cancer in elderly patients. DESIGN--Randomised trial of treatment of operable breast cancer by wedge mastectomy or tamoxifen, with median follow up 24 and 25 months respectively (range 1-63). SETTING--University hospital; most patients from primary catchment area. PATIENTS--135 consecutive patients with breast cancer aged over 70 with operable tumours (less than 5 cm maximum diameter); 68 were allocated to tamoxifen group and 67 to mastectomy group. Histological diagnosis by biopsy. Two incorrect randomisations in each group. Patient characteristics similar in the two groups and all under care of one surgical team. INTERVENTIONS--Mastectomy group received wedge mastectomy plus excision of symptomatic axillary lymph nodes. Tamoxifen group received continuous treatment with tamoxifen 20 mg twice daily. Patients in tamoxifen group received wedge mastectomy if there was sign of local progression. Those in mastectomy group received further excision or radiotherapy for locoregional recurrence and when local treatments had been exhausted or metastatic disease diagnosed they received tamoxifen. END POINT--Treatment efficacy was assessed by local control of disease and by survival. MAIN RESULTS--Mortality from metastatic cancer in tamoxifen group was 7 (10.6%) and in mastectomy group 10 (15.3%) (NS). There was no difference in survival between the two groups. In mastectomy group 70% remained alive and free of local recurrence at 24 months; in tamoxifen group only 47% remained alive and free of local progression. In mastectomy group locoregional recurrence occurred in 16 patients and metastatic disease in 13; in tamoxifen group locoregional progression occurred in 29 patients and metastatic disease in seven. CONCLUSIONS--As a high proportion of patients treated with tamoxifen eventually required surgery treatment of elderly patients with breast cancer should include mastectomy. Optimum treatment may include both mastectomy and tamoxifen.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Breast - pathology</subject><subject>Breast - surgery</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cause of Death</subject><subject>Combined Modality Therapy</subject><subject>Disease progression</subject><subject>Female</subject><subject>Grade 3</subject><subject>Histology</subject><subject>Humans</subject><subject>Lymph Node Excision</subject><subject>Mastectomy</subject><subject>Neoplasia</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local</subject><subject>Older adults</subject><subject>Prospective Studies</subject><subject>Radiotherapy</subject><subject>Random Allocation</subject><subject>Relapse</subject><subject>Risk Factors</subject><subject>Simple mastectomy</subject><subject>Tamoxifen - therapeutic use</subject><issn>0959-8138</issn><issn>1468-5833</issn><issn>1756-1833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU2rEzEUhoMo13K9ezfCgOBGpiaTz9kIUtSq5bpRcReS9OTeqTOTMUn19t-bMqV-bFyF8D7n5RwehB4TvCSEihd22C2bVi6FYHLJCbmHFoQJVXNF6X20wC1va0WoeoiuUtphjBsqVSv4BbqghLZEtgtkVmGYTOxSGKvgq8GkDC6H4VD97PJtlc0Q7joPY-VDrHIEk7vxpoJ-C7E_VFP5wpjTDIcJorE9VLZwKVfOjA7iI_TAmz7B1em9RJ_fvP60Wtebj2_frV5tassJzzUoxyhwzoEZbJWygHnTGCa4oB4777w3nlnn261viXAWqAVvYWtZIzk39BK9nHunvR1g68pe0fR6it1g4kEH0-m_k7G71TfhhyaKYSpJKXh2Kojh-x5S1kOXHPS9GSHsk5aKUSYpL-DTf8Bd2MexHKeJlIIRSklTKDxTLoaUIvjzKgTroz9d_OniTx_96eKvjDz584TzwMnW73yXcojnuHRgzFtZ8nrOu2Lx7pyb-E0LSSXX119W-uv7DaUfrtd6XfjnM3_c5L_b_QI37MB6</recordid><startdate>19880820</startdate><enddate>19880820</enddate><creator>Robertson, J. F.</creator><creator>Todd, J. H.</creator><creator>Ellis, I. O.</creator><creator>Elston, C. W.</creator><creator>Blamey, R. W.</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>LK8</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19880820</creationdate><title>Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer</title><author>Robertson, J. F. ; Todd, J. H. ; Ellis, I. O. ; Elston, C. W. ; Blamey, R. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b515t-e8c43e555e4a0b88be0522a46563f0cfcffaf4bcf9df916cbe3befbedb42755a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Breast - pathology</topic><topic>Breast - surgery</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cause of Death</topic><topic>Combined Modality Therapy</topic><topic>Disease progression</topic><topic>Female</topic><topic>Grade 3</topic><topic>Histology</topic><topic>Humans</topic><topic>Lymph Node Excision</topic><topic>Mastectomy</topic><topic>Neoplasia</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local</topic><topic>Older adults</topic><topic>Prospective Studies</topic><topic>Radiotherapy</topic><topic>Random Allocation</topic><topic>Relapse</topic><topic>Risk Factors</topic><topic>Simple mastectomy</topic><topic>Tamoxifen - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robertson, J. F.</creatorcontrib><creatorcontrib>Todd, J. H.</creatorcontrib><creatorcontrib>Ellis, I. O.</creatorcontrib><creatorcontrib>Elston, C. W.</creatorcontrib><creatorcontrib>Blamey, R. W.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robertson, J. F.</au><au>Todd, J. H.</au><au>Ellis, I. O.</au><au>Elston, C. W.</au><au>Blamey, R. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer</atitle><jtitle>BMJ</jtitle><addtitle>BMJ</addtitle><date>1988-08-20</date><risdate>1988</risdate><volume>297</volume><issue>6647</issue><spage>511</spage><epage>514</epage><pages>511-514</pages><issn>0959-8138</issn><eissn>1468-5833</eissn><eissn>1756-1833</eissn><abstract>STUDY OBJECTIVE--Comparison of tamoxifen and mastectomy in treatment of breast cancer in elderly patients. DESIGN--Randomised trial of treatment of operable breast cancer by wedge mastectomy or tamoxifen, with median follow up 24 and 25 months respectively (range 1-63). SETTING--University hospital; most patients from primary catchment area. PATIENTS--135 consecutive patients with breast cancer aged over 70 with operable tumours (less than 5 cm maximum diameter); 68 were allocated to tamoxifen group and 67 to mastectomy group. Histological diagnosis by biopsy. Two incorrect randomisations in each group. Patient characteristics similar in the two groups and all under care of one surgical team. INTERVENTIONS--Mastectomy group received wedge mastectomy plus excision of symptomatic axillary lymph nodes. Tamoxifen group received continuous treatment with tamoxifen 20 mg twice daily. Patients in tamoxifen group received wedge mastectomy if there was sign of local progression. Those in mastectomy group received further excision or radiotherapy for locoregional recurrence and when local treatments had been exhausted or metastatic disease diagnosed they received tamoxifen. END POINT--Treatment efficacy was assessed by local control of disease and by survival. MAIN RESULTS--Mortality from metastatic cancer in tamoxifen group was 7 (10.6%) and in mastectomy group 10 (15.3%) (NS). There was no difference in survival between the two groups. In mastectomy group 70% remained alive and free of local recurrence at 24 months; in tamoxifen group only 47% remained alive and free of local progression. In mastectomy group locoregional recurrence occurred in 16 patients and metastatic disease in 13; in tamoxifen group locoregional progression occurred in 29 patients and metastatic disease in seven. CONCLUSIONS--As a high proportion of patients treated with tamoxifen eventually required surgery treatment of elderly patients with breast cancer should include mastectomy. Optimum treatment may include both mastectomy and tamoxifen.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>3139179</pmid><doi>10.1136/bmj.297.6647.511</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8138 |
| ispartof | BMJ, 1988-08, Vol.297 (6647), p.511-514 |
| issn | 0959-8138 1468-5833 1756-1833 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1840371 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Breast - pathology Breast - surgery Breast cancer Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cause of Death Combined Modality Therapy Disease progression Female Grade 3 Histology Humans Lymph Node Excision Mastectomy Neoplasia Neoplasm Metastasis Neoplasm Recurrence, Local Older adults Prospective Studies Radiotherapy Random Allocation Relapse Risk Factors Simple mastectomy Tamoxifen - therapeutic use |
| title | Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A12%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20mastectomy%20with%20tamoxifen%20for%20treating%20elderly%20patients%20with%20operable%20breast%20cancer&rft.jtitle=BMJ&rft.au=Robertson,%20J.%20F.&rft.date=1988-08-20&rft.volume=297&rft.issue=6647&rft.spage=511&rft.epage=514&rft.pages=511-514&rft.issn=0959-8138&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.297.6647.511&rft_dat=%3Cjstor_pubme%3E29700597%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776413312&rft_id=info:pmid/3139179&rft_jstor_id=29700597&rfr_iscdi=true |